Christina Claus

Schlieren, ZH, Switzerland

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

P329G-engager: a universal mix & match antibody-based adaptor platform for cancer immunotherapy.

Journal: mAbs
Published: December 16, 2025

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

CEA-4-1BBL: CEACAM5-Targeted 4-1BB Ligand Fusion Proteins for Cis Co-Stimulation with CEA-TCB.

Journal: Antibodies (Basel, Switzerland)
Published: September 27, 2025

4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.

4-1BB agonist targeted to fibroblast activation protein α synergizes with radiotherapy to treat murine breast tumor models.

Journal: Journal for immunotherapy of cancer
Published: November 01, 2024

Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL.

Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL.

Journal: Frontiers in pharmacology
Published: July 29, 2024

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

CD19-CD28: an affinity-optimized CD28 agonist for combination with glofitamab (CD20-TCB) as off-the-shelf immunotherapy.

Journal: Blood
Published: November 27, 2023

A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.

A model-based approach leveraging in vitro data to support dose selection from the outset: A framework for bispecific antibodies in immuno-oncology.

Journal: CPT: pharmacometrics & systems pharmacology
Published: July 10, 2023

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.

The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy.

Journal: mAbs
Published: February 02, 2023

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.

Tumor-activated lymph node fibroblasts suppress T cell function in diffuse large B cell lymphoma.

Journal: The Journal of clinical investigation
Published: November 08, 2022

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer.

Journal: Journal for immunotherapy of cancer
Published: February 14, 2020

The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.

The PET-Tracer 89Zr-Df-IAB22M2C Enables Monitoring of Intratumoral CD8 T-cell Infiltrates in Tumor-Bearing Humanized Mice after T-cell Bispecific Antibody Treatment.

Journal: Cancer research
Published: October 18, 2019

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.

Journal: Science translational medicine
Published: October 08, 2018

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell malignancies.

Journal: Blood
Published: December 11, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026